pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
480
stories
May 7, 26
STAT+: FDA revisits a rare cancer treatment it rejected a few months ago
stat
May 7, 26
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
stat
May 7, 26
STAT+: Next-gen Duchenne drug from Entrada disappoints
stat
May 7, 26
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
stat
May 6, 26
STAT+: Oregon hospitals won’t outsource to national physician chain after all
stat
May 6, 26
STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
stat
May 6, 26
Novo hikes guidance on Wegovy pill’s fast sales start
biopharma dive
May 6, 26
STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
stat
May 6, 26
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
stat
May 6, 26
STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more
stat
May 6, 26
Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
endpoints
May 5, 26
STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing
stat
May 5, 26
STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
stat
May 4, 26
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
stat
May 1, 26
Amgen launches late-stage obesity trial in patients who switch from rival drugs
endpoints
May 1, 26
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
stat
May 1, 26
Two biotechs raise a combined $556M in latest spurt of IPOs
biopharma dive
Apr 30, 26
STAT+: FDA wants to exclude weight loss drugs from a compounding list
stat
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive
Apr 30, 26
Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s
endpoints
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
Apr 28, 26
Coultreon banks $125M to support testing of former Galapagos immune drug
biopharma dive
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
Apr 28, 26
Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
endpoints
Apr 24, 26
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
biopharma dive
Apr 23, 26
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
biopharma dive
Apr 23, 26
Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud
endpoints
Apr 22, 26
Merck adds to pharma’s AI push; Roche details MS drug results
biopharma dive
Apr 22, 26
An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?
biopharma dive
Dec 22, 25
Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series A
fiercebiotech
← prev
page 16 of 16
next →
